Description
Summary: The A/T/N biomarker framework (NIA-AA) which is guiding research work in the field of AD has undergone three revisions since its inception in 2011. These have resulted from advancements in the field and from limitations faced by such methodologies regarding validity, scope, accessibility, and representativeness. For example, the 2023 revised framework (still open to feedback - https://aaic.alz.org/nia-aa.asp) states that AD is defined biologically (i.e., via amyloid plaques and tau tangles) and that clinical symptoms, such as memory problems, are not necessary to diagnose AD. Where such a position leaves countries that cannot adhere the A/T/N framework? What will be the fate of classical clinical criteria for AD which requests evidence of cognitive decline to suggest possible/probable AD? In this seminar, I will discuss recent evidence from studies involving newly developed cognitive makers for AD which have shed light on questions such as “which”, “when”, and “why” cognition can be mapped along the clinicopathological continuum of this type of dementia.| Period | 17 Oct 2023 |
|---|---|
| Event title | Espacio Ateneos / Universidad Javeriana |
| Event type | Seminar |
| Location | Bogota, ColombiaShow on map |
| Degree of Recognition | International |